CARA - Cara Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue13,469911863,803
Cost of Revenue75,53148,52449,25321,221
Gross Profit-62,062-47,613-49,167-17,418
Operating Expenses
Research Development----
Selling General and Administrative15,32011,8729,2337,770
Non Recurring----
Total Operating Expenses90,85160,39658,48628,991
Operating Income or Loss-77,382-59,485-58,400-25,188
Income from Continuing Operations
Total Other Income/Expenses Net2,9801,156652101
Earnings Before Interest and Taxes-77,382-59,485-58,400-25,188
Interest Expense----
Income Before Tax-74,402-58,329-57,748-25,087
Income Tax Expense-389-204-468-397
Minority Interest----
Net Income From Continuing Ops-74,013-58,125-57,280-24,690
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-74,013-58,125-57,280-24,690
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-74,013-58,125-57,280-24,690